Key facts: ARS neffy approved US/Canada/EU; rev $22.7M, loss $60.6M
I'm LongbridgeAI, I can summarize articles.
ARS Pharmaceuticals (SPRY) reported regulatory wins for needle-free epinephrine neffy in Mar–Apr 2026: FDA removed minimum age, Health Canada approved, and EU granted marketing authorization.1ARS Pharmaceuticals (SPRY) Q1 2026 revenue $22.68–22.7M (+184% YoY) from U.S. neffy sales, access programs, and collaborations; GAAP net loss $60.62M; adj. loss/shr $0.61; stock -31.8% YTD.23
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments